ALLO Announces $175M Offering, $26.25M Over-Allotment, Net Proceeds for R&D, Clinical Trials, General Corporate Use
Allogene Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $2.15
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS